<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855877</url>
  </required_header>
  <id_info>
    <org_study_id>TRANEX-LCA</org_study_id>
    <nct_id>NCT04855877</nct_id>
  </id_info>
  <brief_title>Oral Administration of Tranexamic Acid in Anterior Cruciate Ligament Surgery Reduce Postoperative Haemarthrosis</brief_title>
  <official_title>Does Oral Administration of Tranexamic Acid in Anterior Cruciate Ligament Arthroscopic Surgery Reduce Postoperative Haemarthrosis and Improve Functional Prognosis?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find superiority relationship between oral and intravenous administration of tranexamic&#xD;
      acid on peroperative and postoperative blood loss, haemarthrosis prevalence and improvement&#xD;
      functional prognosis in anterior cruciate ligament arthroscopy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tranexamic acid is an anti-fibrinolytic drug, recommended in total hip arthroplasty to reduce&#xD;
      peroperative and postoperative hemorrhagic complications. The original character of our study&#xD;
      lies in the serum dosage of tranexamic acid, allowing to correlate the primary objective&#xD;
      (blood loss) with this one. The investigators will focus on the reduction of the risks&#xD;
      associated with the administration of intravenous medicines, the economic aspect and the ease&#xD;
      of use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blinded prospective randomized controlled trial</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patient, anesthesiologist and surgeon are blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of haemarthrosis</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>Postoperative (drainage) blood loss</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Postoperative pain score on numeric ratio scale (NRS) from 0 (no pain) to 10 (worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>72 hours after surgery</time_frame>
    <description>Postoperative pain score on numeric rating scale (NRS) from 0 (no pain) to 10 (worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>7 days after surgery</time_frame>
    <description>Postoperative pain score on numeric rating scale (NRS) from 0 (no pain) to 10 (worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>15 days after surgery</time_frame>
    <description>Postoperative pain score on numeric rating scale (NRS) from 0 (no pain) to 10 (worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluation of functional recovery</measure>
    <time_frame>1 days after surgery</time_frame>
    <description>Tegner activity score from 0 (no activity) to 10 (competitive sport)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluation of functional recovery</measure>
    <time_frame>3 days after surgery</time_frame>
    <description>Tegner activity score from 0 (no activity) to 10 (competitive sport)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluation of functional recovery</measure>
    <time_frame>7 days after surgery</time_frame>
    <description>Tegner activity score from 0 (no activity) to 10 (competitive sport)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluation of functional recovery</measure>
    <time_frame>15 days after surgery</time_frame>
    <description>Tegner activity score from 0 (no activity) to 10 (competitive sport)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>First 30 days after surgery</time_frame>
    <description>Total days of hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Hemorrhage Postoperative</condition>
  <condition>Anterior Cruciate Ligament Rupture</condition>
  <condition>Arthroscopy</condition>
  <condition>Total Blood Loss</condition>
  <arm_group>
    <arm_group_label>Oral Tranexamic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>52 patients scheduled for primary anteriori cruciate ligament surgery by arthroscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>52 patients scheduled for primary anteriori cruciate ligament surgery by arthroscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral tablet</intervention_name>
    <description>Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration</description>
    <arm_group_label>Oral Tranexamic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of lactose tablet (placebo)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary arthroscopic surgery for anterior cruciate ligament reconstruction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal failure with serum creatinine level higher than 1,40 mg/dL&#xD;
&#xD;
          -  Thromboembolic events in last 12 months before surgery&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Congenital or acquired coagulation diseases&#xD;
&#xD;
          -  History of gastric surgery that could lead to malabsorption&#xD;
&#xD;
          -  Diabetic gastro-paresis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas Piette, MD</last_name>
    <phone>003242843824</phone>
    <email>piettenicolas@me.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Carella, MD</last_name>
      <phone>003242843658</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Bini SA, Clarke HD, Schemitsch E, Johnson RL, Memtsoudis SG, Sayeed SA, Sah AP, Della Valle CJ. Tranexamic acid in total joint arthroplasty: the endorsed clinical practice guides of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society. Reg Anesth Pain Med. 2019 Jan;44(1):7-11. doi: 10.1136/rapm-2018-000024. Review.</citation>
    <PMID>30640647</PMID>
  </reference>
  <reference>
    <citation>Muhunthan K, Balakumar S, Navaratnaraja TS, Premakrishna S, Arulkumaran S. Plasma Concentrations of Tranexamic Acid in Postpartum Women After Oral Administration. Obstet Gynecol. 2020 Apr;135(4):945-948. doi: 10.1097/AOG.0000000000003750.</citation>
    <PMID>32168220</PMID>
  </reference>
  <reference>
    <citation>Karaaslan F, Karaoğlu S, Yurdakul E. Reducing Intra-articular Hemarthrosis After Arthroscopic Anterior Cruciate Ligament Reconstruction by the Administration of Intravenous Tranexamic Acid: A Prospective, Randomized Controlled Trial. Am J Sports Med. 2015 Nov;43(11):2720-6. doi: 10.1177/0363546515599629. Epub 2015 Sep 2.</citation>
    <PMID>26337246</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Jean François Brichant</investigator_full_name>
    <investigator_title>Head of Anesthesiology Departement</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemarthrosis</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Exsanguination</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

